Related Experiment Video
Updated: Apr 5, 2026
Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Published on: January 31, 2025
Interleukin-6 as an emerging regulator of renal cell cancer
Katarzyna Kamińska1, Anna M Czarnecka1, Bernard Escudier2
1Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Background:
Our knowledge on the molecular basis of kidney cancer metastasisis still relatively low. About 25-30% of patients suffering from clear cell renal cell carcinoma (ccRCC)present metastatic disease at the time of primary diagnosis. Only 10% of patients diagnosed with stage IV disease survive 5 years and 20-50% of patients diagnosed with localized tumor develop metastases within 3 years. High mortality of patients with this cancer is associated with a large potential for metastasis and resistance to oncologic treatments such as chemo- and radiotherapy. Literature data based on studies conducted on other types of cancers suggest that in metastatic ccRCC, the complex of interleukin-6 (IL-6) and its soluble receptor (sIL-6R; complex IL-6/sIL-6R) and the signal transduction pathway (gp130/STAT3) might play a key role in this process.
Purpose:
Therefore, in this review we focus on the role of IL-6 and its signaling pathways as a factor for development and spread of RCC. Analyzing the molecular basis of cancer spreading will enable the development of prognostic tests, evaluate individual predisposition for metastasis, and produce drugs that target metastases. As the development of effective systemic treatments evolve from advancements in molecular biology, continued studies directed at understanding the genetic and molecular complexities of this disease are critical to improve RCC treatment options.
Insights
Interleukin-6 (IL-6) signaling pathways may drive kidney cancer metastasis. Understanding these molecular mechanisms is crucial for developing new prognostic tests and targeted therapies for renal cell carcinoma (RCC).
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Clear cell renal cell carcinoma (ccRCC) has a high rate of metastasis, with poor survival for stage IV patients.
- Metastatic ccRCC exhibits resistance to conventional treatments like chemotherapy and radiotherapy.
- The interleukin-6 (IL-6)/soluble IL-6 receptor (sIL-6R) complex and gp130/STAT3 pathway are implicated in metastasis of other cancers.
Purpose of the Study:
- To review the role of IL-6 and its signaling pathways in the development and spread of renal cell carcinoma (RCC).
- To analyze the molecular basis of cancer spreading for improved prognostic tests and targeted therapies.
- To highlight the importance of molecular biology advancements in improving RCC treatment options.
Main Methods:
- Literature review focusing on IL-6 signaling in ccRCC metastasis.
- Analysis of molecular mechanisms underlying cancer cell spread.
- Synthesis of current research on gp130/STAT3 pathway involvement.
Main Results:
- The IL-6/sIL-6R complex and gp130/STAT3 pathway are potential key drivers of ccRCC metastasis.
- Understanding these pathways offers insights into cancer progression and treatment resistance.
- This knowledge is foundational for developing novel therapeutic strategies.
Conclusions:
- IL-6 signaling is a critical factor in RCC metastasis.
- Targeting IL-6 pathways could lead to improved prognostic tools and treatments for kidney cancer.
- Further research into these molecular complexities is essential for advancing RCC patient care.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
